Sorrento Therapeutics, Inc. · OTC:SRNE

Sorrento Therapeutics — Investor Presentation (October 2013)

34 slides from Sorrento Therapeutics's investor presentation, October 2013

  1. Slide 1: Sorrento Therapeutics: Next-Generation Cancer Therapeutics

    Slide 1: Sorrento Therapeutics: Next-Generation Cancer Therapeutics

    Sorrento Therapeutics Next-Generation Cancer Therapeutics October 2013

  2. Slide 2: Safe Harbor Statement

    Slide 2: Safe Harbor Statement

    Safe Harbor Statement OTC QB: SRNE This presentation contains "forward-looking statements" as that term is defined under the Private Securities Litigation Reform Act of 1995 (PSLRA), including statements regarding expectations, beliefs or intentions regarding our business, technologies and products

  3. Slide 3: Management Team and Board of Directors

    Slide 3: Management Team and Board of Directors

    Management Team and Board of Directors Henry Ji, Ph.D. • Inventor of G-MAB® Technology Board of Directors President, CEO & • President & CEO of Stratagene Genomics • VP of CombiMatrix and Stratagene David Webb, Ph.D. - Chairman Director Celgene (former San Diego site head) Ernst-Günther Afting, M.D.

  4. Slide 4: Investment Highlights

    Slide 4: Investment Highlights

    Investment Highlights Late Stage Oncology Drug with Exclusive US and EU Rights • Addresses multi-billion dollar paclitaxel market Cynviloq™ • Abbreviated regulatory pathway (“bioequivalence”) for approval • Bioequivalence registration trial in 2014 (study direct costs ~ $5M) • Product launch in 1H 2

  5. Slide 5: Sorrento's Next-Generation Cancer Therapeutics

    Slide 5: Sorrento's Next-Generation Cancer Therapeutics

    Sorrento’s Next-Generation Cancer Therapeutics G-MAB® • High-diversity human Ab library • Lead mAb programs include PD-L1, PD-1, and CCR2 Cynviloq™ TUMOR • FTO and no stacking royalties  Next-generation Abraxane® • Bioequivalence (BE) pathway for approval • Efficacy demonstrated • US and EU rights

  6. Slide 6: Pipeline

    Slide 6: Pipeline

    Pipeline INDICATION Metastatic Breast Cancer Non-Small Cell Lung Cancer } 505(b)(2) Bioequivalence 1H 2014 1H 2015 Cynviloq™ Pancreatic Cancer (BE* or sNDA) Bladder Cancer (sNDA) Multiple Ovarian Cancer (sNDA) INDICATION > TARGET Strategic Oncology > PD-L1, PD-1, CXCR5 1H 2015 G-MAB® Inflammation >

  7. Slide 7: Oncology Franchise Cynviloq

    Slide 7: Oncology Franchise Cynviloq

    Oncology Franchise Cynviloq™ 7

  8. Slide 8: Cynviloq is the 3rd Generation Paclitaxel Therapy

    Slide 8: Cynviloq is the 3rd Generation Paclitaxel Therapy

    Cynviloq is the 3rd Generation Paclitaxel Therapy Maximum Peak Generation Formulation Tolerated Dose Product Sales 1st Cremophor EL Taxol® excipient: 175 mg/m2 ~ $1.6B (WW in 2000) paclitaxel Polyoxyethylated castor oil 2nd Biological polymer: 260 mg/m2 Est. >$1.7B* (US) Abraxane® Mean size Donor-de

  9. Slide 9: Cynviloq is a High Value Proposition

    Slide 9: Cynviloq is a High Value Proposition

    Cynviloq is a High Value Proposition 1. Exclusive US and EU Rights 2. Cynviloq efficacy demonstrated in Phase 2 and Phase 3 studies 3. FDA concurred a. Available data support pursuing 505(b)(2) regulatory pathway b. Bioequivalence (BE) study sufficient for approval of indications in Abraxane® label

  10. Slide 10: Bioequivalence = Efficient Pathway to Market

    Slide 10: Bioequivalence = Efficient Pathway to Market

    Bioequivalence = Efficient Pathway to Market • Bioequivalence registration study in breast cancer patients (2014) - 12 months of duration (including patient recruitment) - Direct trial cost ~$5M • Dose: 260 mg/m2 Cycle 1 Abraxane® Cynviloq™ • Infusion time: 30 min (50 patients) (50 patients) • Durat

  11. Slide 11: Cynviloq Market Opportunity

    Slide 11: Cynviloq Market Opportunity

    Cynviloq Market Opportunity ~70,000 patients treated with paclitaxel-based regimen in 1st line 100,000 # of Patients Treated in 1st line (US Only; 2012) 90,000 Other regimens ~55,000 patients with 80,000 PAC+ treated paclitaxel as 1st line therapy in MBC, NSCLC & OC 70,000 60,000 50,000 15,903 PC pa

  12. Slide 12: Cynviloq Advantages

    Slide 12: Cynviloq Advantages

    Cynviloq Advantages Cynviloq Cynviloq™ Abraxane® Taxol® Advantage Maximum Tolerated Dose Potential for >300 260 175 (mg/m2) higher efficacy Rapid reconstitution: Convenience for busy no foaming concerns ● ● practices and pharmacies No donor-derived human serum albumin (HSA) ● ● No viral / prion conc

  13. Slide 13: Potential to Expand Label Indications: 2nd Line Bladder Cancer

    Slide 13: Potential to Expand Label Indications: 2nd Line Bladder Cancer

    Potential to Expand Label Indications – For Example: 2nd Line Bladder Cancer Cynviloq Best Supportive Care Phase 2 (Korea)* Phase 2 (Japan) **/ Phase 3 (EU)*** 260-300 mg/m2 q3w n=23** / n=108*** n=34# Overall Response Rate (ORR) 21% - / 0%*** Progression Free Survival 2.7 M - / 1.5 M*** Overall Sur

  14. Slide 14: Next Steps for Cynviloq

    Slide 14: Next Steps for Cynviloq

    Next Steps for Cynviloq 1. Bioequivalence (BE) trial: 2014 2. NDA filing: 2014 / 2015 3. Approval: 2016 a. Metastatic Breast Cancer (MBC) and Non-Small Cell Lung Cancer (NSCLC) b. Future Abraxane® indications (Pancreatic cancer and Melanoma) 4. Product launch for MBC and NSCLC: 2016 5. sNDA planning

  15. Slide 15: Therapeutic Antibody Engine G-MAB

    Slide 15: Therapeutic Antibody Engine G-MAB

    Therapeutic Antibody Engine G-MAB® 15

  16. Slide 16: G-MAB: Library of Therapeutic Antibodies

    Slide 16: G-MAB: Library of Therapeutic Antibodies

    G-MAB®: Library of Therapeutic Antibodies • Proprietary technology • Very high library diversity: - RNA amplification used for 2.1 x 1016 distinct antibodies library generation - Freedom-To-Operate • Fully human antibodies • No stacking royalties • High successful screening hit rate Most Difficult T

  17. Slide 17: Anti-PD-L1 mAbs Exhibit Potent Activity

    Slide 17: Anti-PD-L1 mAbs Exhibit Potent Activity

    Anti-PD-L1 mAbs Exhibit Potent Activity Immune Modulation* Tumor Mouse Model** *** Tumor Growth Inhibition (%) T Cell Activation (%) IFN-γ (pg/mL) IL-2 (pg/mL) Day Competitor mAb Sorrento mAb * mAbs @ 0.05 mg/mL ** xenograft model using H1975 human NSCLC cells; % inhibition relative to control mAb t

  18. Slide 18: Anti-PD-1 mAbs Exhibit Potent Immune Modulation

    Slide 18: Anti-PD-1 mAbs Exhibit Potent Immune Modulation

    IL-2 Concentration (pg/mL) INF-γ Concentration (pg/mL) Sorrento mAb Competitor mAbs T cell Activation (%CD25+) normalized to untreated control 18 Anti-PD-1 mAbs Exhibit Potent Immune Modulation

  19. Slide 19: Potent Antibody against Difficult GPCR Target

    Slide 19: Potent Antibody against Difficult GPCR Target

    Potent Antibody against Difficult GPCR Target* 3.5 Cell Binding mAb (EC50 – nM) Sorrento 0.17 3 Competitor 21 2.5 Disease Score** 2 Untreated PBS Sorrento D1 mAb therapeutic 1.5 1 0.5 0 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 Days After Disease Induction * Sorre

  20. Slide 20: Targeted Drug Formulation Platform ADC/AfDC

    Slide 20: Targeted Drug Formulation Platform ADC/AfDC

    Targeted Drug Formulation Platform ADC/AfDC 20

  21. Slide 21: Antibody Drug Conjugates (ADC)

    Slide 21: Antibody Drug Conjugates (ADC)

    Antibody Drug Conjugates (ADC) Key Components: 1. Target-specific internalizing antibody 2. Potent cytotoxic prodrugs 3. Linker and conjugation chemistries Drug released in CANCER CELL 21

  22. Slide 22: Sorrento ADCs Demonstrate Enhanced Activity

    Slide 22: Sorrento ADCs Demonstrate Enhanced Activity

    Sorrento ADCs Demonstrate Enhanced Activity Anti-VEGFR2 ADC* Anti-c-Met ADC** Relative Cell Viability Relative Cell Viability (% of non treated cells) (% of non treated cells) p value p value < 0.0001 < 0.0001 IgG Concentration (nM) IgG Concentration (nM) Leading Competitor mAb Toxin Control Sorrent

  23. Slide 23: Sorrento anti-GPCR ADCs Demonstrate Enhanced Activity

    Slide 23: Sorrento anti-GPCR ADCs Demonstrate Enhanced Activity

    Sorrento anti-GPCR ADCs Demonstrate Enhanced Activity Anti-CXCR3 ADC* Anti-CXCR5 ADC** Relative Cell Viability Relative Cell Viability (% of non treated cells) (% of non treated cells) p value = 0.0015** p value = 0.0035** IgG Concentration (nM) IgG Concentration (nM) Sorrento naked mAb Toxin Contro

  24. Slide 24: Antibody formulated Drug Conjugates (AfDC)

    Slide 24: Antibody formulated Drug Conjugates (AfDC)

    Current AntibodyParadigm formulated of Cancer Drug Conjugates Therapy (AfDC) Key Features: 1. Approved chemotherapeutics with known safety profile 2. No internalization required 3. Multiple mAbs / drug combinations 4. Effective against heterogeneous tumors Drug released in TUMOR 24

  25. Slide 25: G-MAB, ADC and AfDC Pipeline

    Slide 25: G-MAB, ADC and AfDC Pipeline

    G-MAB®, ADC and AfDC Pipeline G-MAB® Antibody PD-L1 (STI-A100X) 1H 2015 PD-L1 (STI-A100X) AfDC PD-1 (STI-A110X) 1H 2015 ONCOLOGY VEGFR2-ADC (STI-A0168) 2H 2015 Multiple EGFR (STI-A020X) ADC/AfDC c-Met (STI-A150X) ADC/AfDC Strategic PD-L1 (STI-B010X) INFLAMMATION RAGE (STI-B120X) CGRP (STI-B150X) Par

  26. Slide 26: Positioned to Become Oncology Leader

    Slide 26: Positioned to Become Oncology Leader

    Positioned to Become Oncology Leader Cynviloq™ G-MAB® ADC/AfDC 26

  27. Slide 27: Small Molecule Oncology Drug, Antibody Library and ADC Company Valuations

    Slide 27: Small Molecule Oncology Drug, Antibody Library and ADC Company Valuations

    Small Molecule Oncology Drug, Antibody Library and ADC Company Valuations Company Small Molecule Antibody Targeted Mkt Cap* Oncology Drug Platform Drug Delivery NSCLC, MBC Antibody Sorrento: SRNE (Ph3/Registration Trial) Library ADC & AfDC $130M Puma: PBYI MBC (Phase 3) ~$1.6B Pre-revenue Clovis: CL

  28. Slide 28: Investment Highlights

    Slide 28: Investment Highlights

    Investment Highlights Late Stage Oncology Drug with Exclusive US and EU Rights • Addresses multi-billion dollar paclitaxel market Cynviloq™ • Abbreviated regulatory pathway (“bioequivalence”) for approval • Bioequivalence registration trial in 2014 (study direct costs ~ $5M) • Product launch in 1H 2

  29. Slide 29: Financials & Capitalization

    Slide 29: Financials & Capitalization

    Financials & Capitalization Cash and Cash Equivalents $5.7M Total Debt $5.0M Common Stock Outstanding 16,479,734 Options Granted & Outstanding (1) 512,600 Warrants Outstanding (2) 39,250 Current Capitalization 17,034,784 Pro Forma Issuances: IgDraSol Milestone 1,306,272 Assignment Agreement 80,000 P

  30. Slide 30: Sorrento Therapeutics Contact

    Slide 30: Sorrento Therapeutics Contact

    Sorrento Therapeutics Next-Generation Cancer Therapeutics Contact: Henry Ji President and CEO hji@sorrentotherapeutics.com (858) 668-6923

  31. Slide 31: Cynviloq: Interim Results from Phase 3 MBC Study

    Slide 31: Cynviloq: Interim Results from Phase 3 MBC Study

    Cynviloq: Interim Results from Phase 3 MBC Study Phase 3 study in MBC Summary of Clinical Exposures Stage Trial Patients Phase 1 MTD 80 MBC, NSCLC, Phase 2 259 PC, OC, BC Phase 3 MBC 105 Post Market MBC, NSCLC 502 (Safety) Total 946 US approval for Abraxane® in MBC and NSCLC for non-inferiority agai

  32. Slide 32: Simulated PK Parameters Supportive of BE

    Slide 32: Simulated PK Parameters Supportive of BE

    Simulated PK Parameters Supportive of BE: Cynviloq™ vs. Abraxane® Comparison of mean non-compartmental pharmacokinetic parameters of Cynviloq™ (T) and Abraxane® (R) @ 260 mg/m2 with 30 min infusion time: Cmax Ratio AUCinf Ratio (ng/mL) Cmax(T)/Cmax(R) (ng*h/mL) AUCinf(T)/AUCinf(R) CynviloqTM 19486 2

  33. Slide 33: Why Antibody Therapeutics

    Slide 33: Why Antibody Therapeutics

    Why Antibody Therapeutics  Clinical track record of safety and efficacy  Most successful drug class today  Excellent target specificity and affinity  Limited off-target effects  Predictable PK/PD properties  Good serum half life  Effector functions  Recruitment of patient’s immune system aga

  34. Slide 34: Top Selling Therapeutic Antibodies

    Slide 34: Top Selling Therapeutic Antibodies

    Top 10 Selling Therapeutic Antibodies (>$50B) 2012 Sales mAb Target Companies (US$ billions)* US Global Humira (Adalimumab) TNF Abbott; Esai 4.4 9.3 Enbrel (Etanercept) TNF Amgen; Pfizer; Takeda 4.0 8.0 Rituxan (Rituximab) CD20 Roche 3.3 7.0 Remicade (Infliximab) TNF J&J; Merck; Mitsubishi Tanabe 3.

Source: Internet Archive copy of sorrentotherapeutics.com

More decks from Sorrento Therapeutics, Inc.

All 41 Sorrento Therapeutics decks